Skip to content Skip to footer
Subscribe Now
Exclusive Coverage Global PHT Expo & Summit 2023
EVENTS

Exclusive Coverage: Global PHT Expo & Summit 2023

The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India.Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
February 27, 2023

Read more

Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: AfliberceptStrength: 2 mg (0.05 mL)Dosage Form: Injection (intravitreal)Mechanism of Action: VEGF-A and PlGF inhibitorsFirst Approval: US (18 Nov 2011), EU (27 Nov 2012)Revenue1EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 2022

Read more

13th Summit on Biosimilars & Innovator Biologics
EVENTS

13th Summit on Biosimilars & Innovator Biologics

The American Conference Institute invites you to attend the 13th Summit on Biosimilars & Innovator Biologics on June 28-29, 2022, back in-person in Boston! Gain government and industry insights on the Innovator and Biosimilars Marketplace from the U.S. FTC, USPTO, AAM, BIO and leading In-House Counsel.We’ve reached an inflection point in the United States. With another major wave of loss…
May 23, 2022

Read more

Insights+ Key Biosimilars Events of May 2021
INSIGHTS+

Insights+ Key Biosimilars Events of May 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of May, Samsung initiated patient enrollment in the P-III…
June 3, 2021

Read more

Insights+ Key Biosimilars Events of April 2020
INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…
May 8, 2020

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]